AstraZeneca 082120

feature image
AstraZeneca’s Imfinzi has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer, in combination with etoposide plus a choice of platinum chemotherapy.

From a chartist point of view, the stock consolidates above a key support at 8310. As long as this level is not broken, a bounce would be expected towards 9113 at first.

Source : TradingVIEW, Gain Capital

Open an account in minutes

Experience award-winning platforms with fast and secure execution.

Sign up for our interactive livestreams

Our interactive livestreams, led by our industry experts, come highly recommended and can help provide your trading with the edge it needs.
Economic Calendar